TO COMPARE THE SAFETY & EFFICACY OF AZILSARTAN VERSUS OLMESARTAN AS ADD ON THERAPY TO CHLORTHALIDONE IN COEXISTING HYPERTENSION WITH TYPE-2 DIABETES MELLITUS RANDOMISED CONTROLLED TRIAL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024756

Enrollment

100

Registered

2020-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E115- Type 2 diabetes mellitus with circulatory complications

Interventions

Intervention1: AZILSARTAN AND CHLORTHALIDONE: AZILSARTAN 40 mg + CHLORTHALIDONE 12.5mg orally once in a day after meals for 1 year Control Intervention1: OLMESARTAN AND CHLORTHALIDONE: OLMESARTAN 20

Eligibility

Inclusion criteria

Inclusion criteria: Willing to give informed consent for the study. Consenting adult patients of age > 18 yrs of either sex. Ambulatory patients diagnosed with hypertension with type 2 diabetes mellitus who have blood pressure > 130/80 mmhg on chlorthalidone therapy

Exclusion criteria

Exclusion criteria: Patients age less than 18 years. Patients not willing to give written informed consent Type 1 diabetes mellitus patients Stage IV chronic kidney disease (GFRâ?? Congestive heart failure NYHA classes II-IV. Recent major cardiovascular events ( Pregnant and lactating females Known hypersensitivity to drugs

Design outcomes

Primary

Measure	Time frame
to check safety and efficacy of trial drugs in patients of hypertension with type 2 diabetesTimepoint: Safety and efficacy checked at the end of first, third and sixth month after initiating the treatment	—

Secondary

Measure	Time frame
to check safety and efficacy of trial drugs in patients of hypertension with type 2 diabetesTimepoint: Safety and efficacy checked in 1 3 and 6 month	—

Countries

India

Contacts

Public ContactPROFESSOR D K KANSAL

DR. RPGMC TANDA

deekshasharma1125@gmail.com9459317717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026